Recombinant protein production in prokaryotic and eukaryotic heterologous hosts for serological assays for COVID-19

原核和真核异源宿主中的重组蛋白生产用于 COVID-19 血清学检测

• 批准号: 551372-2020
• 负责人: Leaver, Chad
• 金额: $ 3.41万
• 依托单位: Seneca College of Applied Arts and Technology
• 依托单位国家: 加拿大
• 项目类别: Applied Research Rapid Response to COVID-19
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=696152
• 关键词: Recombinant; protein; production; prokaryotic; eukaryotic

Kenota Health (formerly ExVivo Labs), Kitchener, ON, has developed a complete sample-to-result lateral flow immunoassay testing system for point-of-care medical diagnostics. Kenota's technology fully integrates blood collection, purification and quantitative analyte analysis with an intuitive easy-to-use interface. Kenota has designed IgG and IgM antibody tests that can determine COVID-19 exposure in 10 minutes. Kenota plans to collaborate with Seneca's School of Biological Science and Applied Chemistry to develop processes and procedures for manufacturing SARS-CoV-2 recombinant proteins. The proposed project will lower the cost of testing and reduce the risk of delays in availability of tests. These serological assays are critical in determining the incidence of a pathogen in a population. In future, the ability to identify sensitive and specific SARS-CoV-2 antibodies could support screening of health care workers, minimizing the risk of viral spread to colleagues and other patients.

位于安大略省基奇纳的 Kenota Health（前身为 ExVivo Labs）开发了完整的样本到结果侧向层析技术 用于即时医疗诊断的免疫分析测试系统。凯诺塔技术全面融合血液 通过直观易用的界面进行收集、纯化和定量分析。基诺塔有 设计了 IgG 和 IgM 抗体测试，可在 10 分钟内确定 COVID-19 暴露情况。基诺塔计划 与塞内卡生物科学和应用化学学院合作开发工艺和 生产 SARS-CoV-2 重组蛋白的程序。拟议的项目将降低成本 测试并降低测试可用性延迟的风险。这些血清学检测对于确定 病原体在人群中的发病率。未来，能够识别敏感且特异的 SARS-CoV-2 抗体可以支持对医护人员进行筛查，最大限度地减少病毒传播给同事的风险， 其他患者。